Piha-Paul S, Olwill S, Hamilton E, Tolcher A, Pohlmann P, Liu S
Clin Cancer Res. 2024; 31(2):288-298.
PMID: 39235868
PMC: 11739778.
DOI: 10.1158/1078-0432.CCR-24-1552.
Matson A, Hullsiek R, Dixon K, Wang S, Lindstedt A, Friess R
J Immunother Cancer. 2024; 12(7).
PMID: 39053944
PMC: 11284835.
DOI: 10.1136/jitc-2024-008959.
Ahn M, Kim E, Choi Y, Chae C, Kim P, Kim S
PLoS One. 2024; 19(6):e0305261.
PMID: 38923962
PMC: 11207149.
DOI: 10.1371/journal.pone.0305261.
Kopp A, Guan J, Johnston C, Vance S, Legg J, Galson-Holt L
AAPS J. 2024; 26(4):68.
PMID: 38862748
PMC: 11497593.
DOI: 10.1208/s12248-024-00937-3.
Ma Y, Luo F, Zhang Y, Liu Q, Xue J, Huang Y
Cell Rep Med. 2024; 5(2):101414.
PMID: 38330942
PMC: 10897605.
DOI: 10.1016/j.xcrm.2024.101414.
Impact of tissue penetration and albumin binding on design of T cell targeted bispecific agents.
Kopp A, Kwon H, Johnston C, Vance S, Legg J, Galson-Holt L
Neoplasia. 2024; 48:100962.
PMID: 38183712
PMC: 10809211.
DOI: 10.1016/j.neo.2023.100962.
Fcγ receptors and immunomodulatory antibodies in cancer.
Galvez-Cancino F, Simpson A, Costoya C, Matos I, Qian D, Peggs K
Nat Rev Cancer. 2023; 24(1):51-71.
PMID: 38062252
DOI: 10.1038/s41568-023-00637-8.
Interrogating ligand-receptor interactions using highly sensitive cellular biosensors.
Funk M, Leitner J, Gerner M, Hammerler J, Salzer B, Lehner M
Nat Commun. 2023; 14(1):7804.
PMID: 38016944
PMC: 10684770.
DOI: 10.1038/s41467-023-43589-1.
A model-based approach leveraging in vitro data to support dose selection from the outset: A framework for bispecific antibodies in immuno-oncology.
Sanchez J, Claus C, Albrecht R, Gaillard B, Marinho J, McIntyre C
CPT Pharmacometrics Syst Pharmacol. 2023; 12(11):1804-1818.
PMID: 37964753
PMC: 10681425.
DOI: 10.1002/psp4.13065.
Lactate oxidase nanocapsules boost T cell immunity and efficacy of cancer immunotherapy.
Cao Z, Xu D, Harding J, Chen W, Liu X, Wang Z
Sci Transl Med. 2023; 15(717):eadd2712.
PMID: 37820006
PMC: 10720694.
DOI: 10.1126/scitranslmed.add2712.
Agonism of 4-1BB for immune therapy: a perspective on possibilities and complications.
Salek-Ardakani S, Zajonc D, Croft M
Front Immunol. 2023; 14:1228486.
PMID: 37662949
PMC: 10469789.
DOI: 10.3389/fimmu.2023.1228486.
FcγR requirements and costimulatory capacity of Urelumab, Utomilumab, and Varlilumab.
Leitner J, Egerer R, Waidhofer-Sollner P, Grabmeier-Pfistershammer K, Steinberger P
Front Immunol. 2023; 14:1208631.
PMID: 37575254
PMC: 10413977.
DOI: 10.3389/fimmu.2023.1208631.
Axicabtagene Ciloleucel in Combination with the 4-1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11.
Jain M, Miklos D, Jacobson C, Timmerman J, Sun J, Nater J
Clin Cancer Res. 2023; 29(20):4118-4127.
PMID: 37527011
PMC: 10570684.
DOI: 10.1158/1078-0432.CCR-23-0916.
CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation.
Gao J, Wang Z, Jiang W, Zhang Y, Meng Z, Niu Y
J Immunother Cancer. 2023; 11(6).
PMID: 37364935
PMC: 10410885.
DOI: 10.1136/jitc-2023-006704.
A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable pancreatic adenocarcinoma.
Heumann T, Judkins C, Li K, Lim S, Hoare J, Parkinson R
Nat Commun. 2023; 14(1):3650.
PMID: 37339979
PMC: 10281953.
DOI: 10.1038/s41467-023-39196-9.
Targeting Co-Stimulatory Receptors of the TNF Superfamily for Cancer Immunotherapy.
Muller D
BioDrugs. 2022; 37(1):21-33.
PMID: 36571696
PMC: 9836981.
DOI: 10.1007/s40259-022-00573-3.
The Bispecific Tumor Antigen-Conditional 4-1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies.
Nelson M, Fritzell S, Miller R, Werchau D, Van Citters D, Nilsson A
Mol Cancer Ther. 2022; 22(1):89-101.
PMID: 36343381
PMC: 9808321.
DOI: 10.1158/1535-7163.MCT-22-0395.
First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors.
Hamid O, Chiappori A, Thompson J, Doi T, Hu-Lieskovan S, Eskens F
J Immunother Cancer. 2022; 10(10).
PMID: 36302562
PMC: 9621185.
DOI: 10.1136/jitc-2022-005471.
Targeting 4-1BB for tumor immunotherapy from bench to bedside.
Wang Y, Ji W, Jiao H, Lu A, Chen K, Liu Q
Front Immunol. 2022; 13:975926.
PMID: 36189243
PMC: 9523430.
DOI: 10.3389/fimmu.2022.975926.
Development and characterization of a novel human CD137 agonistic antibody with anti-tumor activity and a good safety profile in non-human primates.
Gao Y, Yang T, Liu H, Song N, Dai C, Ding Y
FEBS Open Bio. 2022; 12(12):2166-2178.
PMID: 36176235
PMC: 9714380.
DOI: 10.1002/2211-5463.13494.